Phase 2 Bladder Cancer Trial, Recruiting NCT05232136 Sponsor: Binhui Biopharmaceutical Co., Ltd. Condition: Bladder Cancer
Back to Bladder Cancer

Phase 2 Bladder Cancer Trial, Recruiting

NCT05232136
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 80 years old (inclusive), of any gender
  • Your bladder cancer has not invaded the muscle layer, and is classified as high grade at stage Ta, T1, or Tis
  • You have already tried a first-line bladder wash (instillation) treatment that did not work, and your bladder has been kept (or surgery to remove the whole bladder is not suitable for you for another reason)
  • During your most recent bladder surgery (TURBT), tissue samples and urine tests came back showing no remaining cancer signs
  • Tests of your upper urinary tract (kidneys and ureters) showed no tumors, and you have never had chemotherapy or radiation therapy for bladder cancer
  • You are generally active and able to care for yourself (confirm with trial site)
  • Your doctor expects you to live for more than 1 year
  • Your blood counts, kidney function, liver function, and blood clotting results are all within acceptable ranges (confirm with trial site for specific numbers)
  • You agree to use effective contraception during treatment and for at least 3 months afterward
  • Any herpes infection you have had ended at least 3 months ago
  • You are willing to follow the trial requirements and sign a consent form

Who may not be able to join:

  • Your bladder cancer has grown into the muscle layer, or has spread to other parts of the body
  • You had complications after your bladder surgery, or bladder wash treatments cannot be carried out for you
  • You have a known allergy to GM-CSF products or to any ingredient in the study drug
  • You have a serious medical condition, such as severe heart disease, stroke-related disease, uncontrolled diabetes, uncontrolled high blood pressure, severe infection, or an active stomach or bowel ulcer
  • You are expected to need chemotherapy or radiation therapy during the study period
  • You currently have an active infection, an unexplained fever above 38.5°C, or an ongoing urinary or bladder infection that has not fully cleared (unless it was treated with antibiotics and resolved at least 7 days after finishing the course)
  • You have a condition that weakens your immune system (such as HIV), an active hepatitis B infection with detectable virus levels, or active hepatitis C infection
  • You are currently pregnant or breastfeeding
  • You have taken another experimental drug or antiviral treatment within the past 4 weeks
  • You have taken immune-suppressing medications (such as cyclosporine, tacrolimus, or antithymocyte globulin) in the past 3 months
  • You have taken part in a cancer vaccine trial (such as dendritic cell therapy or heat shock vaccine) in the past 12 months
  • You have a history of substance abuse, alcohol dependency, or drug abuse
  • You have been diagnosed with another cancer in the past 5 years, with some exceptions for certain low-risk or successfully treated cancers (confirm with trial site)
  • You have an active autoimmune disease, or a history of one that may come back — though certain manageable conditions such as type 1 diabetes, controlled low thyroid, controlled celiac disease, or skin conditions not needing systemic treatment may be exceptions (confirm with trial site)
  • You have used steroid medications as a treatment within the past 14 days, or regularly take other immune-suppressing medicines — though some limited uses such as inhalers, eye drops, or short-term preventive steroids may be exceptions (confirm with trial site)
  • The trial doctors have any other concern that makes participation unsuitable for you

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 13601332989

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Binhui Biopharmaceutical Co., Ltd.
Registry
ClinicalTrials.gov
Start date
11 July 2022
Est. completion
1 June 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

AEs; Relapse Free Survival Rate at 6 months; Relapse Free Survival Rate at 12 months; Rate of disease progression

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov